Susceptibility of different mouse wild type strains to develop diet-induced nafld/afld-associated liver disease

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Fengler, Vera H I ^a   Macheiner, Tanja ^a   Kessler, Sonja M ^b   Czepukojc, Beate ^b   Gemperlein, Katja ^b,c   Müller, Rolf ^b,c   Kiemer, Alexandra K ^b   Magnes, Christoph ^d   Haybaeck, Johannes ^a   Lackner, Carolin ^a   Sargsyan, Karine ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b SAARLAND UNIVERSITY   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d JOANNEUM RESEARCH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

129SV MOUSE; ALCOHOLIC FATTY LIVER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CD-1 MOUSE; CONTROLLED STUDY; DISEASE PREDISPOSITION; GENETIC BACKGROUND; HEPATITIS; HISTOPATHOLOGY; LIPID COMPOSITION; MALE; MOUSE; MOUSE STRAIN; NONALCOHOLIC FATTY LIVER; NONHUMAN; STRAIN DIFFERENCE; WILD TYPE; 129 MOUSE; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; DISEASE MODEL; FAT INTAKE; FATTY LIVER, ALCOHOLIC; GENETICS; INBRED MOUSE STRAIN; LIPID DIET; LIVER; LIVER FUNCTION TEST; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; SPECIES DIFFERENCE; SUBCUTANEOUS FAT; WEIGHT GAIN;

ALANINE AMINOTRANSFERASE; ALCOHOL; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CHOLESTEROL; FAT INTAKE; FATTY ACID; TRIACYLGLYCEROL;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BIOMARKERS; CHOLESTEROL; DIET, HIGH-FAT; DIETARY FATS; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; ETHANOL; FATTY ACIDS, NONESTERIFIED; FATTY LIVER, ALCOHOLIC; LIVER; LIVER FUNCTION TESTS; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, INBRED STRAINS; NON-ALCOHOLIC FATTY LIVER DISEASE; SPECIES SPECIFICITY; SUBCUTANEOUS FAT; TRIGLYCERIDES; WEIGHT GAIN;

EID: 84969872401     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0155163     Document Type: Article

References (83)

1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43(2 Suppl 1):S99-S112. PMID: 16447287
2. Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. Journal of gastroenterology and hepatology. 2010; 25(4):672-90. doi: 10.1111/j.1440-1746.2010.06253.x PMID: 20492324
3. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011; 140(1):124-31. doi: 10.1053/j.gastro.2010.09.038 PMID: 20858492
4. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6):1387-95. PMID: 15565570
5. Mann RE, Smart RG, Govoni R. The epidemiology of alcoholic liver disease. Alcohol research & health: the journal of the National Institute on Alcohol Abuse and Alcoholism. 2003; 27(3):209-19.
6. Adachi M, Brenner DA. Clinical syndromes of alcoholic liver disease. Digestive diseases (Basel, Switzerland). 2005; 23(3-4):255-63.
7. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. The American journal of the medical sciences. 2005; 330(6):326-35. PMID: 16355018
8. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012; 142(4):711-25.e6. doi: 10.1053/j.gastro.2012.02.003 PMID: 22326434
9. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic proceedings. 1980; 55(7):434-8. PMID: 7382552
10. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. PMID: 15915461
11. Day CP. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver international: official journal of the International Association for the Study of the Liver. 2006; 26(9):1021-8.
12. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. American journal of clinical pathology. 2007; 128(5):837-47. PMID: 17951208
13. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature genetics. 2008; 40(12):1461-5. doi: 10.1038/ng.257 PMID: 18820647
14. Sookoian S, Rosselli MS, Gemma C, Burgueno AL, Fernandez Gianotti T, Castano GO, et al. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor gamma coactivator 1alpha promoter. Hepatology. 2010; 52(6):1992-2000. doi: 10.1002/hep.23927 PMID: 20890895
15. Buch S, Stickel F, Trepo E. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. 2015;47(12):1443-8.
16. Anstee QM, Seth D, Day CP. Genetic Factors That Affect Risk of Alcoholic and Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2016.
17. Holmen OL, Zhang H, Fan Y, Hovelson DH, Schmidt EM, Zhou W, et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nature genetics. 2014; 46(4):345-51. doi: 10.1038/ng.2926 PMID: 24633158
18. Surakka I, Horikoshi M, Magi R, Sarin AP, Mahajan A, Lagou V, et al. The impact of low-frequency and rare variants on lipid levels. 2015;47(6):589-97.
19. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS genetics. 2011; 7(3):e1001324. doi: 10.1371/journal.pgen.1001324 PMID: 21423719
20. Dongiovanni P, Valenti L, Rametta R, Daly AK, Nobili V, Mozzi E, et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut. 2010; 59(2):267-73. doi: 10.1136/gut.2009.190801 PMID: 20176643
21. Jellema A, Zeegers MP, Feskens EJ, Dagnelie PC, Mensink RP. Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: a meta-analysis of 27 studies. Diabetologia. 2003; 46(7):990-5. PMID: 12819898
22. Vazquez-Chantada M, Gonzalez-Lahera A, Martinez-Arranz I, Garcia-Monzon C, Regueiro MM, Garcia-Rodriguez JL, et al. Solute carrier family 2 member 1 is involved in the development of nonalcoholic fatty liver disease. Hepatology. 2013; 57(2):505-14. doi: 10.1002/hep.26052 PMID: 22961556
23. Zintzaras E, Stefanidis I, Santos M, Vidal F. Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? Hepatology. 2006; 43(2):352-61. PMID: 16440362
24. Maher JJ. New insights from rodent models of fatty liver disease. Antioxidants & redox signaling. 2011; 15(2):535-50.
25. Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, et al. Model of nonalcoholic steatohepatitis. The American journal of clinical nutrition. 2004; 79(3):502-9. PMID: 14985228
26. Almind K, Kahn CR. Genetic determinants of energy expenditure and insulin resistance in diet-induced obesity in mice. Diabetes. 2004; 53(12):3274-85. PMID: 15561960
27. Biddinger SB, Almind K, Miyazaki M, Kokkotou E, Ntambi JM, Kahn CR. Effects of diet and genetic background on sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome. Diabetes. 2005; 54(5):1314-23. PMID: 15855315
28. Burcelin R, Crivelli V, Dacosta A, Roy-Tirelli A, Thorens B. Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. American journal of physiology Endocrinology and metabolism. 2002; 282(4):E834-42. PMID: 11882503
29. Clapper JR, Hendricks MD, Gu G, Wittmer C, Dolman CS, Herich J, et al. Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. American journal of physiology Gastrointestinal and liver physiology. 2013; 305(7): G483-95. doi: 10.1152/ajpgi.00079.2013 PMID: 23886860
30. Duval C, Thissen U, Keshtkar S, Accart B, Stienstra R, Boekschoten MV, et al. Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57BL/6 mice. Diabetes. 2010; 59(12):3181-91. doi: 10.2337/db10-0224 PMID: 20858684
31. Gabele E, Dostert K, Dorn C, Patsenker E, Stickel F, Hellerbrand C. A new model of interactive effects of alcohol and high-fat diet on hepatic fibrosis. Alcoholism, clinical and experimental research. 2011; 35(7):1361-7. doi: 10.1111/j.1530-0277.2011.01472.x PMID: 21463337
32. Ito M, Suzuki J, Tsujioka S, Sasaki M, Gomori A, Shirakura T, et al. Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet. Hepatology research: the official journal of the Japan Society of Hepatology. 2007; 37(1):50-7.
33. Kahle M, Horsch M, Fridrich B, Seelig A, Schultheiss J, Leonhardt J, et al. Phenotypic comparison of common mouse strains developing high-fat diet-induced hepatosteatosis. Molecular metabolism. 2013; 2(4):435-46. doi: 10.1016/j.molmet.2013.07.009 PMID: 24327959
34. Koza RA, Nikonova L, Hogan J, Rim JS, Mendoza T, Faulk C, et al. Changes in gene expression foreshadow diet-induced obesity in genetically identical mice. PLoS genetics. 2006; 2(5):e81. PMID: 16733553
35. Shearn CT, Smathers RL, Jiang H, Orlicky DJ, Maclean KN, Petersen DR. Increased dietary fat contributes to dysregulation of the LKB1/AMPK pathway and increased damage in a mouse model of early-stage ethanol-mediated steatosis. The Journal of nutritional biochemistry. 2013.
36. Comhair TM, Garcia Caraballo SC, Dejong CH, Lamers WH, Kohler SE. Dietary cholesterol, female gender and n-3 fatty acid deficiency are more important factors in the development of non-alcoholic fatty liver disease than the saturation index of the fat. Nutrition & metabolism. 2011; 8:4.
37. Wouters K, van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, Lutjohann D, et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology. 2008; 48(2):474-86. doi: 10.1002/hep.22363 PMID: 18666236
38. Schultz A, Barbosa-da-Silva S, Aguila MB, Mandarim-de-Lacerda CA. Differences and similarities in hepatic lipogenesis, gluconeogenesis and oxidative imbalance in mice fed diets rich in fructose or sucrose. Food & function. 2015; 6(5):1684-91.
39. Volynets V, Spruss A, Kanuri G, Wagnerberger S, Bischoff SC, Bergheim I. Protective effect of bile acids on the onset of fructose-induced hepatic steatosis in mice. Journal of lipid research. 2010; 51(12):3414-24. doi: 10.1194/jlr.M007179 PMID: 20847296
40. Bergheim I, Weber S, Vos M, Kramer S, Volynets V, Kaserouni S, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. Journal of hepatology. 2008; 48(6):983-92. doi: 10.1016/j.jhep.2008.01.035 PMID: 18395289
41. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. Journal of hepatology. 2003; 39(6):978-83. PMID: 14642615
42. Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology. 2009; 50(4):1094-104. doi: 10.1002/hep.23122 PMID: 19637282
43. Ishimoto T, Lanaspa MA, Rivard CJ, Roncal-Jimenez CA, Orlicky DJ, Cicerchi C, et al. High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology. 2013; 58(5):1632-43. doi: 10.1002/hep.26594 PMID: 23813872
44. Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V, et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology. 2010; 52(3):934-44. doi: 10.1002/hep.23797 PMID: 20607689
45. Luo Y, Burrington CM, Graff EC, Zhang J, Judd RL, Suksaranjit P, et al. Metabolic phenotype and adipose and liver features in the high fat Western diet-induced mouse model of obesity-linked NAFLD. American journal of physiology Endocrinology and metabolism. 2015:ajpendo.00319.2015.
46. Siddiqui RA, Xu Z, Harvey KA, Pavlina TM, Becker MJ, Zaloga GP. Comparative study of the modulation of fructose/sucrose-induced hepatic steatosis by mixed lipid formulations varying in unsaturated fatty acid content. Nutrition & metabolism. 2015; 12:41.
47. Syn WK, Yang L, Chiang DJ, Qian Y, Jung Y, Karaca G, et al. Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice. Liver international: official journal of the International Association for the Study of the Liver. 2009; 29(8):1262-72.
48. Gyamfi MA, Damjanov I, French S, Wan YJ. The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury. Biochemical pharmacology. 2008; 75(4):981-95. PMID: 18036573
49. Kirsch R, Clarkson V, Shephard EG, Marais DA, Jaffer MA, Woodburne VE, et al. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. Journal of gastroenterology and hepatology. 2003; 18(11):1272-82. PMID: 14535984
50. Ganz M, Csak T, Szabo G. High fat diet feeding results in gender specific steatohepatitis and inflammasome activation. World journal of gastroenterology: WJG. 2014; 20(26):8525-34. doi: 10.3748/wjg.v20.i26.8525 PMID: 25024607
51. Kamada Y, Kiso S, Yoshida Y, Chatani N, Kizu T, Hamano M, et al. Estrogen deficiency worsens steatohepatitis in mice fed high-fat and high-cholesterol diet. American journal of physiology Gastrointestinal and liver physiology. 2011; 301(6):G1031-43. doi: 10.1152/ajpgi.00211.2011 PMID: 21885686
52. Maina V, Sutti S, Locatelli I, Vidali M, Mombello C, Bozzola C, et al. Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice. Clinical science. 2012; 122(11):545-53. doi: 10.1042/CS20110366 PMID: 22142284
53. Clugston RD, Jiang H, Lee MX, Piantedosi R, Yuen JJ, Ramakrishnan R, et al. Altered hepatic lipid metabolism in C57BL/6 mice fed alcohol: a targeted lipidomic and gene expression study. Journal of lipid research. 2011; 52(11):2021-31. doi: 10.1194/jlr.M017368 PMID: 21856784
54. Laggai S, Simon Y, Ranssweiler T, Kiemer AK, Kessler SM. Rapid chromatographic method to decipher distinct alterations in lipid classes in NAFLD/NASH. World journal of hepatology. 2013; 5(10):558-67. doi: 10.4254/wjh.v5.i10.558 PMID: 24179615
55. Simon Y, Kessler SM, Gemperlein K, Bohle RM, Muller R, Haybaeck J, et al. Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis. World journal of gastroenterology: WJG. 2014; 20(47):17839-50. doi: 10.3748/wjg.v20.i47.17839 PMID: 25548482
56. Hill DB, Marsano L, Cohen D, Allen J, Shedlofsky S, McClain CJ. Increased plasma interleukin-6 concentrations in alcoholic hepatitis. The Journal of laboratory and clinical medicine. 1992; 119(5):547-52. PMID: 1583411
57. Mizuhara H, O'Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K, et al. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. The Journal of experimental medicine. 1994; 179(5):1529-37. PMID: 8163936
58. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003; 38(2):413-9. PMID: 12883485
59. Simon Y, Kessler SM, Bohle RM, Haybaeck J, Kiemer AK. The insulin-like growth factor 2 (IGF2) mRNA-binding protein p62/IGF2BP2-2 as a promoter of NAFLD and HCC? Gut. 2014; 63(5):861-3. doi: 10.1136/gutjnl-2013-305736 PMID: 24173291
60. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. The Journal of clinical investigation. 1997; 99(5):846-54. PMID: 9062341
61. Farrell GC, Mridha AR, Yeh MM, Arsov T, Van Rooyen DM, Brooling J, et al. Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype. Liver international: official journal of the International Association for the Study of the Liver. 2014; 34(7):1084-93.
62. Van Rooyen DM, Larter CZ, Haigh WG, Yeh MM, Ioannou G, Kuver R, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology. 2011; 141(4):1393-403, 403.e1-5. doi: 10.1053/j.gastro.2011.06.040 PMID: 21703998
63. Caballero F, Fernandez A, De Lacy AM, Fernandez-Checa JC, Caballeria J, Garcia-Ruiz C. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. Journal of hepatology. 2009; 50(4):789-96. doi: 10.1016/j.jhep.2008.12.016 PMID: 19231010
64. McClain CJ, Barve S, Deaciuc I. Good fat/bad fat. Hepatology. 2007; 45(6):1343-6. PMID: 17538963
65. Saito K, Uebanso T, Maekawa K, Ishikawa M, Taguchi R, Nammo T, et al. Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis. Scientific reports. 2015; 5:12466. doi: 10.1038/srep12466 PMID: 26289793
66. Listenberger LL, Han X, Lewis SE, Cases S, Farese RV Jr, Ory DS, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100(6):3077-82. PMID: 12629214
67. Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell metabolism. 2012; 15(5):665-74. doi: 10.1016/j.cmet.2012.04.004 PMID: 22560219
68. Wilson CG, Tran JL, Erion DM, Vera NB, Febbraio M, Weiss EJ. Hepatocyte-specific disruption of CD36 attenuates fatty liver and improves insulin sensitivity in HFD fed mice. Endocrinology. 2015: en20151866.
69. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007; 46(4):1081-90. PMID: 17654743
70. Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T, et al. Gene expression in human NAFLD. American journal of physiology Gastrointestinal and liver physiology. 2008; 294(5):G1281-7. doi: 10.1152/ajpgi.00074.2008 PMID: 18388185
71. Summers SA. Sphingolipids and insulin resistance: the five Ws. Current opinion in lipidology. 2010; 21(2):128-35. doi: 10.1097/MOL.0b013e3283373b66 PMID: 20216312
72. Raichur S, Wang ST, Chan PW, Li Y, Ching J, Chaurasia B, et al. CerS2 haploinsufficiency inhibits beta-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell metabolism. 2014; 20(4):687-95. doi: 10.1016/j.cmet.2014.09.015 PMID: 25295789
73. Kasumov T, Li L, Li M, Gulshan K, Kirwan JP, Liu X, et al. Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis. PloS one. 2015; 10(5):e0126910. doi: 10.1371/journal.pone.0126910 PMID: 25993337
74. Wang X, Cao Y, Fu Y, Guo G, Zhang X. Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease. Lipids in health and disease. 2011; 10:234. doi: 10.1186/1476-511X-10-234 PMID: 22165986
75. Kessler SM, Simon Y, Gemperlein K, Gianmoena K, Cadenas C, Zimmer V, et al. Fatty acid elongation in non-alcoholic steatohepatitis and hepatocellular carcinoma. International journal of molecular sciences. 2014; 15(4):5762-73. doi: 10.3390/ijms15045762 PMID: 24714086
76. Laggai S, Kessler SM, Boettcher S, Lebrun V, Gemperlein K, Lederer E, et al. The IGF2 mRNA binding protein p62/IGF2BP2-2 induces fatty acid elongation as a critical feature of steatosis. Journal of lipid research. 2014; 55(6):1087-97. PMID: 24755648
77. Videla LA, Rodrigo R, Araya J, Poniachik J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free radical biology & medicine. 2004; 37(9):1499-507.
78. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clinical science. 2004; 106(6):635-43. PMID: 14720121
79. Hanada S, Strnad P, Brunt EM, Omary MB. The genetic background modulates susceptibility to mouse liver Mallory-Denk body formation and liver injury. Hepatology. 2008; 48(3):943-52. doi: 10.1002/hep.22436 PMID: 18697208
80. Dubuquoy C, Robichon C, Lasnier F, Langlois C, Dugail I, Foufelle F, et al. Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes. Journal of hepatology. 2011; 55(1):145-53. doi: 10.1016/j.jhep.2010.10.024 PMID: 21145868
81. He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. The Journal of biological chemistry. 2010; 285(9):6706-15. doi: 10.1074/jbc.M109.064501 PMID: 20034933
82. Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjaerg-Hansen A, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nature genetics. 2014; 46(4):352-6. doi: 10.1038/ng.2901 PMID: 24531328
83. Haybaeck J, Stumptner C, Thueringer A, Kolbe T, Magin TM, Hesse M, et al. Genetic background effects of keratin 8 and 18 in a DDC-induced hepatotoxicity and Mallory-Denk body formation mouse model. Laboratory investigation; a journal of technical methods and pathology. 2012; 92(6):857-67. doi: 10.1038/labinvest.2012.49 PMID: 22449798